It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
This study reports the clinical course of two patients with osteogenesis imperfecta who received prenatal human fetal mesenchymal stem cell (MSC) transplantation and postnatal boosting with same-donor MSCs. Findings suggest that prenatal transplantation of allogeneic human fetal MSCs in osteogenesis imperfecta appears safe and is of likely clinical benefit and that retransplantation with same-donor cells is feasible. Further studies are required.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
2 Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
3 Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan
4 Department of Women's and Children's Health and Neuro-pediatric Unit, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
5 Experimental Fetal Medicine Group, Department of Obstetrics and Gynecology, Yong Loo Lin School of Medicine and National University of Singapore, Singapore
6 Departments of Pathology and Medicine (Medical Genetics), University of Washington, Seattle, Washington, USA
7 Department of Genetics, Children's Hospital of Eastern Ontario and Department of Pediatrics, University of Ottawa, Ottawa, Canada
8 Orthopedic Unit, Uppsala University Hospital, Uppsala, Sweden
9 Women's and Children's Health, Uppsala University, Uppsala, Sweden
10 Centre for Clinical Research, University of Queensland, Brisbane, Australia
11 Department of Pediatrics, Yong Loo Lin School of Medicine and National University of Singapore, Singapore
12 Division of Medical Genetics, Department of Pediatrics, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan
13 Center for Hematology and Regenerative Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Hematology Center, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
14 Experimental Fetal Medicine Group, Department of Obstetrics and Gynecology, Yong Loo Lin School of Medicine and National University of Singapore, Singapore; Department of Reproductive Medicine, Women's and Children's Hospital, Singapore; Cancer and Stem Cell Biology, Duke-National University of Singapore Graduate Medical School, Singapore